Aqueous pharmaceutical composition
AssigneeJCR Pharmaceuticals Co., Ltd.
InventorsHidehito YASUKAWA, Yuka YAMAGUCHI, Shinji OKABE
Life of this patent
Estimating the term…
Abstract
Aqueous pharmaceutical compositions containing a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, which are stable enough to be marketed, are disclosed. The aqueous pharmaceutical composition, for example, comprises the fusion protein of the antibody and the lysosomal enzyme at a concentration of 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and is adjusted to pH 5.0 to 7.5.
Claims29
An aqueous pharmaceutical composition comprising a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, at a concentration 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and a pH 5.0 to 7.5.
An aqueous pharmaceutical composition comprising a fusion protein of an antibody and a lysosomal enzyme as an active ingredient at a concentration 1.0 to 10 mg/mL, sodium chloride at a concentration of 0.6 to 1.0 mg/mL, sucrose at a concentration of 55 to 95 mg/mL, a nonionic surfactant at a concentration 0.15 to 1 mg/mL, a buffer at a concentration 10 to 30 mM, and the pH is 5.5 to 7.0.
Dependencies are inferred from the claim text.